Encephalitis Clinical Trial
Official title:
Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population. Open Label, Randomized, Active Controlled, Phase 3 Study
The primary objective is to assess the systemic and local safety profile of purified inactivated Japanese Encephalitis Virus (JEV) vaccine IC51 administered in two doses in a 28 days interval up to Month 7 after the first IC51 vaccination in a pediatric population from endemic regions.
Open-label, randomized, active controlled Phase 3 study in children aged ≥ 2 months to < 18 years. Subjects aged ≥ 2 months to < 12 months were randomized in a 2:1 ratio to receive IC51 (0.25 ml dose) or Prevnar® as a safety comparator. Children aged ≥ 12 months to < 3 years and ≥ 12 years to < 18 years were randomized in a 3:1 ratio to receive IC51 (0.25 ml dose < 3 years, 0.5 ml ≥ 12 years) or HAVRIX®720 as safety comparator. For subjects aged ≥ 3 years to < 12 years, a dose finding run-in phase was performed. A total of 200 subjects were randomized 1:1 to receive either the 0.25 ml or the 0.5 ml dose of IC51, and the appropriate dose was determined based on an interim analysis. After this run-in phase, 300 further children in this age group were randomized 2:1 to receive either 0.5 ml of IC51 or HAVRIX®720. Immunogenicity was be studied in a subgroup of 30 children aged ≥ 2 months to < 12 months; 125 children aged ≥ 12 months to < 3 years and 140 children ≥ 12 years to < 18 years. For the age group of ≥ 3 to < 12 years immunogenicity was assessed in the 200 children enrolled during the dose-finding run-in phase. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02538094 -
tDCS and Cognition in Adults With Multiple Sclerosis or Encephalitis
|
N/A | |
| Completed |
NCT00381433 -
Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid
|
Phase 1 | |
| Completed |
NCT00031486 -
Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir
|
Phase 3 | |
| Completed |
NCT00069303 -
Natural History of West Nile Virus Infection
|
N/A | |
| Completed |
NCT02906631 -
Epidemiology and Prognosis of Encephalitis in Intensive Care
|
||
| Completed |
NCT02367664 -
A Clinical Trial for Inactivated Japanese Encephalitis Vaccine in Healthy Chinese Infants
|
Phase 3 | |
| Completed |
NCT00314132 -
Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.
|
Phase 3 | |
| Terminated |
NCT00927953 -
Treatment of West Nile Virus With MGAWN1
|
Phase 2 | |
| Recruiting |
NCT05393492 -
Regulating Emotions and Behaviors After Brain Injury
|
N/A | |
| Terminated |
NCT04361344 -
Neurodegeneration Markers and Neurological Course in Severe Covid-19 Infection
|
N/A | |
| Recruiting |
NCT04460599 -
Neurological Features During COVID19
|
||
| Recruiting |
NCT04372615 -
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
|
Phase 2 | |
| Completed |
NCT02714959 -
IL-2 in Refractory Autoimmune Encephalitis
|
Phase 1/Phase 2 | |
| Completed |
NCT01092507 -
A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers
|
Phase 3 | |
| Not yet recruiting |
NCT04722328 -
Establishment of Prevention and Control System of Central Nervous System Infection
|
||
| Recruiting |
NCT06067750 -
Comparison of Narcotrend and Cerebral Function Analysing Monitor in Intensive Care to Monitor Seizures and Deep Sedation
|
||
| Not yet recruiting |
NCT06368648 -
CoMind Early Feasibility Study
|
||
| Completed |
NCT02526550 -
Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX
|
Phase 4 | |
| Completed |
NCT01694524 -
Nervous System Infections Among Patients With Febrile Seizure
|
N/A | |
| Completed |
NCT04080921 -
Stem Cell Transplantation In-patient With Neurological Sequelae Due to Encephalitis or Meningitis
|
Phase 1/Phase 2 |